- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
![andrew ward benzinga](https://investingnews.com/media-library/andrew-ward-benzinga.png?id=27736419&width=1200&height=800&quality=80&coordinates=0%2C0%2C0%2C0)
Amid the heated debate in the psychedelic space and patent ethics, MagicMed Industries continues to develop a library of novel psychedelic derivatives which can be commercialized, according to Andrew Ward and Natan Ponieman in an article published on www.benzinga.com.
Amid the heated debate in the psychedelic space and patent ethics, MagicMed Industries continues to develop a library of novel psychedelic derivatives which can be commercialized, according to Andrew Ward and Natan Ponieman in an article published on www.benzinga.com.
“The risk of going through those processes as required by law is extremely high. And if there’s no way for investors to recover their investment, then they won’t fund it. And then these drugs, which might be lifesaving drugs, will never get approved and society will never benefit from them. So there’s a value to patents,” says Dr. Joseph Tucker, CEO of MagicMed, a company developing second-generation psychedelics.
The article explains that If a company obtains several strong and important patents, it can leverage them to prevent competition. However, many of the molecules being researched today in the psychedelics space either exist in nature or are old enough to be public domain.
Ward and Poneiman wrote that Tucker doesn’t believe these types of patents should be granted, since in his view, most of the applications of psychedelics that are currently under research were already in use decades ago and were not discovered by the companies doing the research.
“We’re definitely filing patents, but the patents that we’re filing on are for new molecules being used in ways that have not been done before,” Tucker explained further.
MagicMed is focusing on discovering and testing new molecules that will then be licensed out to other companies in the space for them to commercialize.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.